Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody

Lenalidomide induced response in a patient with follicular lymphoma of the skin and an... case report memo (2013) 6:123–126 DOI 10.1007/s12254-013-0089-5 Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody Cathrin Skrabs · Christian Sillaber · Ana-Iris Schiefer · Ingrid Simonitsch-Klupp · Thomas Staudinger · Monique Putman · Werner Rabitsch · Ulrich Jaeger Received: 20 March 2013 / Accepted: 21 May 2013 / Published online: 18 June 2013 © Springer-Verlag Wien 2013 Abstract meric antibodies against rituximab were verified in an Background Patients with follicular lymphoma ineligi- early stage of disease, rendering further use of the drug ble for standard treatment with the anti-CD20 antibody impossible. After five treatment lines he developed pro- rituximab represent a considerable challenge as they re- gressive follicular lymphoma with skin involvement, quire alternative therapeutic approaches. which was treated with lenalidomide monotherapy. Patient and methods We describe a patient who expe- Results Six cycles of lenalidomide monotherapy (25  mg rienced a severe episode of serum sickness. Antichi- orally for 21 days, 1 week off ) led to a very good partial response rendering the patient eligible for autologous stem cell transplantation. Data on efficacy of lenalido- U. Jaeger, MD () · C. Skrabs · C. Sillaber mide in follicular lymphoma are reviewed. Department of Medicine I, Division of Hematology http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/lenalidomide-induced-response-in-a-patient-with-follicular-lymphoma-of-ET1sQt8hoC
Publisher
Springer Journals
Copyright
Copyright © 2013 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-013-0089-5
Publisher site
See Article on Publisher Site

Abstract

case report memo (2013) 6:123–126 DOI 10.1007/s12254-013-0089-5 Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody Cathrin Skrabs · Christian Sillaber · Ana-Iris Schiefer · Ingrid Simonitsch-Klupp · Thomas Staudinger · Monique Putman · Werner Rabitsch · Ulrich Jaeger Received: 20 March 2013 / Accepted: 21 May 2013 / Published online: 18 June 2013 © Springer-Verlag Wien 2013 Abstract meric antibodies against rituximab were verified in an Background Patients with follicular lymphoma ineligi- early stage of disease, rendering further use of the drug ble for standard treatment with the anti-CD20 antibody impossible. After five treatment lines he developed pro- rituximab represent a considerable challenge as they re- gressive follicular lymphoma with skin involvement, quire alternative therapeutic approaches. which was treated with lenalidomide monotherapy. Patient and methods We describe a patient who expe- Results Six cycles of lenalidomide monotherapy (25  mg rienced a severe episode of serum sickness. Antichi- orally for 21 days, 1 week off ) led to a very good partial response rendering the patient eligible for autologous stem cell transplantation. Data on efficacy of lenalido- U. Jaeger, MD () · C. Skrabs · C. Sillaber mide in follicular lymphoma are reviewed. Department of Medicine I, Division of Hematology

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 18, 2013

References

  • A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin’s lymphoma
  • Current controversies in follicular lymphoma
    Aurora, V; Winter, JN
  • ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
    Dreyling, M; Ghielmini, M; Marcus, R
  • Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma
    O’Connor, OA; Wright, J; Moskowitz, C
  • Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study
    Kahl, BS; Bartlett, NL; Leonard, JP
  • Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma
    Witzig, TE; Wiernik, PH; Moore, T
  • Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan
    DeMonaco, NA; Jacobs, SA
  • Rituximab-induced serum sickness in a patient with follicular lymphoma
    Disperati, P; Hicks, LK; Buckstein, R
  • Serum sickness with an elevated level of human antichimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura
    Goto, S; Goto, H; Tanoshima, R
  • Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumor activity of rituximab in vivo
    Reddy, N; Hernandez-Ilizaliturri, FJ; Deeb, G
  • Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo
    Lentzsch, S; LeBlanc, R; Podar, K
  • Phase II trial of lenalidomide—dexamethasone—rituximab in relapsed or refractory indolent B-Cell or mantle cell lymphomas resistant to rituximab
    Ahmadi, T; Chong, EA; Gordon, A
  • Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma
    Wiernik, PH; Lossos, IS; Tuscano, JM
  • An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma
    Witzig, TE; Vose, JM; Zinzani, PL
  • Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response
    Chanan-Khan, A; Miller, KC; Lawrence, D